- Report
- January 2024
- 150 Pages
Global
From €4681EUR$4,850USD£4,016GBP
- Report
- March 2024
- 197 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- March 2024
- 199 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- January 2024
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- December 2023
- 200 Pages
Global
From €4826EUR$5,000USD£4,140GBP
- Report
- July 2022
- 150 Pages
Global
From €5743EUR$5,950USD£4,926GBP
- Report
- June 2020
- 114 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- January 2024
- 104 Pages
Global
From €3500EUR$3,884USD£3,107GBP
- Report
- January 2021
- 143 Pages
China, Global
From €3000EUR$3,330USD£2,663GBP
- Book
- October 2019
- 720 Pages
Daptomycin is an antibiotic used to treat a variety of bacterial infections. It is a lipopeptide antibiotic, which means it is composed of both a lipid and a peptide. It works by disrupting the cell membrane of the bacteria, causing it to become leaky and eventually die. Daptomycin is used to treat skin and soft tissue infections, as well as complicated and serious infections such as endocarditis and bacteremia. It is also used to treat infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
Daptomycin is generally well-tolerated and has few side effects. It is usually administered intravenously, but can also be given orally in some cases. It is often used in combination with other antibiotics to treat more serious infections.
The daptomycin market is a growing segment of the antibiotics market. It is used to treat a variety of bacterial infections, and is generally well-tolerated with few side effects. It is often used in combination with other antibiotics to treat more serious infections.
Some companies in the daptomycin market include Cubist Pharmaceuticals, Merck, Pfizer, and Novartis. Show Less Read more